MajorSNRI×Lipid-lowering agent of the fibrate class
Updated · Methodology
Mechanism
In the liver, CYP1A2 and CYP2D6 metabolise duloxetine (duloxetine SmPC, European Medicines Agency, EMA). Strong CYP1A2 inhibitors raise duloxetine levels: fluvoxamine, a strong inhibitor of this enzyme, reduced duloxetine clearance by about 77% and increased its area under the concentration–time curve (AUC) 6-fold (duloxetine SmPC, EMA). According to the Spanish SmPC, gemfibrozil strongly inhibits CYP2C8, CYP2C9, CYP2C19 and CYP1A2 (Lopid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), while the US label mentions CYP1A2 inhibition only from in vitro studies and does not call it strong (Lopid label, US Food and Drug Administration, FDA). The pair has not been studied, and the documents give no figure for how much duloxetine levels would rise. Both drugs are highly bound to plasma proteins, and the documents of both mention possible displacement of other drugs from this binding. Duloxetine, however, showed no such effect with warfarin (Lopid SmPC, AEMPS; duloxetine prescribing information, FDA).
Symptoms
The documents describe no symptoms linked to this combination. With strong CYP1A2 inhibitors, the risk of a fall in blood pressure on standing, fainting and falls may be greater (duloxetine prescribing information, US Food and Drug Administration, FDA). Duloxetine itself can raise blood pressure, up to a hypertensive crisis, especially in people with pre-existing hypertension (duloxetine SmPC, European Medicines Agency, EMA). Gemfibrozil most often causes dyspepsia. It can also cause muscle inflammation and damage with pain, weakness and raised creatine phosphokinase (CPK), as well as raised liver enzymes (Lopid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
Do not give duloxetine together with strong CYP1A2 inhibitors (duloxetine SmPC, European Medicines Agency, EMA). The US label says to avoid this combination (duloxetine prescribing information, US Food and Drug Administration, FDA). Only fluvoxamine, ciprofloxacin and enoxacin are contraindicated by name (duloxetine SmPC, EMA). Gemfibrozil is not among them, but according to the Spanish SmPC it strongly inhibits CYP1A2 (Lopid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). By the letter of the documents, the instruction on strong inhibitors therefore also applies to gemfibrozil. Use duloxetine with caution together with drugs that may impair its metabolism, and in people with hypertension or heart disease monitor blood pressure, especially during the first month (duloxetine SmPC, EMA). If blood pressure rises persistently, consider reducing the duloxetine dose or tapering it off (EMA). With symptomatic orthostatic hypotension, falls or syncope, consider dose reduction or discontinuation (FDA). Use duloxetine with caution together with other drugs associated with liver injury (duloxetine SmPC, EMA). During gemfibrozil treatment, check liver function regularly and stop gemfibrozil if abnormalities persist (Lopid SmPC, AEMPS). Stop gemfibrozil in case of diffuse muscle pain, muscle weakness or creatine phosphokinase (CPK) more than 5 times the upper limit of normal (Lopid SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: LOPID (gemfibrozil tablets, USP) prescribing information (2024)– FDA DailyMed, LOPID (gemfibrozil), Parke-Davis Div of Pfizer, 2024
- EMA: Cymbalta 30 mg cápsulas duras gastrorresistentes – ficha técnica (texto EMA en CIMA) (2026)– EMA SmPC vía AEMPS CIMA, nº 04296001 (EU/1/04/296), secciones 4.4 y 4.5
- EMA: Ficha técnica: Duloxetina, Cymbalta (EU/1/04/296), sección 4.4 (2024)– EMA, ficha técnica Cymbalta, EU/1/04/296 (CIMA nregistro 04296001), texto publicado por la EMA, PDF de 05/2024, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Duloxetine delayed-release capsules (duloxetine) prescribing information (2026)– FDA, DailyMed, Lupin Pharmaceuticals, setid 829a4f51-c882-4b64-81f3-abfb03a52ebe, revised 05/2026, sections 4, 5.2, 5.4, 5.5, 7.1–7.17 and 12.2
- AEMPS: Ficha técnica: Gemfibrozilo, Lopid 600 mg (nº registro 58832), sección 4.4 (2025)– AEMPS, CIMA, nº registro 58832 (Lopid 600 mg comprimidos recubiertos con película, Pfizer), revisión 12/2025, secciones 4.2, 4.3, 4.4, 4.5 y 5.2